| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Cytoplasmic and Nuclear | 24 | 2006 | 858 | 2.790 |
Why?
|
| Diabetic Angiopathies | 14 | 2019 | 803 | 2.110 |
Why?
|
| Arteriosclerosis | 20 | 2004 | 1055 | 2.100 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 8 | 2011 | 61 | 2.030 |
Why?
|
| Thiazolidinediones | 17 | 2014 | 461 | 1.910 |
Why?
|
| PPAR alpha | 11 | 2019 | 175 | 1.850 |
Why?
|
| PPAR gamma | 10 | 2014 | 484 | 1.840 |
Why?
|
| Transcription Factors | 34 | 2023 | 12130 | 1.680 |
Why?
|
| Diabetes Mellitus, Type 2 | 36 | 2024 | 12149 | 1.650 |
Why?
|
| Muscle, Smooth, Vascular | 7 | 2019 | 1492 | 1.580 |
Why?
|
| Cardiovascular Diseases | 52 | 2024 | 15502 | 1.540 |
Why?
|
| Atherosclerosis | 22 | 2024 | 3407 | 1.490 |
Why?
|
| Hypolipidemic Agents | 12 | 2024 | 609 | 1.480 |
Why?
|
| Fatty Acids | 17 | 2024 | 1808 | 1.450 |
Why?
|
| Retinoids | 4 | 2019 | 99 | 1.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 22 | 2024 | 3246 | 1.300 |
Why?
|
| Dicarboxylic Acids | 3 | 2024 | 77 | 1.300 |
Why?
|
| Glucagon-Like Peptides | 7 | 2024 | 153 | 1.250 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2014 | 146 | 1.250 |
Why?
|
| Hypoglycemic Agents | 19 | 2024 | 3085 | 1.060 |
Why?
|
| Endothelium, Vascular | 21 | 2015 | 4431 | 1.060 |
Why?
|
| Inflammation | 25 | 2024 | 10774 | 1.040 |
Why?
|
| Retinoid X Receptors | 3 | 2011 | 91 | 0.950 |
Why?
|
| Lipase | 3 | 2013 | 325 | 0.910 |
Why?
|
| Transcription, Genetic | 16 | 2020 | 7593 | 0.890 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2019 | 224 | 0.830 |
Why?
|
| Coronary Artery Disease | 16 | 2024 | 6403 | 0.830 |
Why?
|
| Lipoprotein(a) | 7 | 2024 | 480 | 0.780 |
Why?
|
| Aorta | 4 | 2022 | 2041 | 0.750 |
Why?
|
| Lipid Metabolism | 11 | 2020 | 1902 | 0.730 |
Why?
|
| Retinal Dehydrogenase | 4 | 2014 | 78 | 0.730 |
Why?
|
| Cholesterol | 10 | 2021 | 2905 | 0.710 |
Why?
|
| Dyslipidemias | 9 | 2019 | 868 | 0.700 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2019 | 28 | 0.700 |
Why?
|
| Lipoproteins, HDL | 3 | 2013 | 676 | 0.690 |
Why?
|
| Lipids | 7 | 2019 | 3341 | 0.640 |
Why?
|
| Triglycerides | 12 | 2021 | 2461 | 0.630 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 3801 | 0.600 |
Why?
|
| Transcription Factor RelA | 3 | 2015 | 254 | 0.590 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 8 | 2015 | 691 | 0.580 |
Why?
|
| Retinal Diseases | 1 | 2023 | 705 | 0.570 |
Why?
|
| Cholesterol, LDL | 13 | 2023 | 2382 | 0.570 |
Why?
|
| Diabetes Complications | 5 | 2019 | 1315 | 0.540 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2020 | 634 | 0.530 |
Why?
|
| Adipose Tissue | 7 | 2020 | 3313 | 0.520 |
Why?
|
| PPAR delta | 3 | 2013 | 40 | 0.510 |
Why?
|
| Diabetes Mellitus | 14 | 2024 | 5841 | 0.500 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 699 | 0.500 |
Why?
|
| Osteogenesis | 2 | 2019 | 1273 | 0.490 |
Why?
|
| Lipoproteins, VLDL | 3 | 2011 | 201 | 0.490 |
Why?
|
| Adipose Tissue, White | 3 | 2020 | 365 | 0.480 |
Why?
|
| Lipoprotein Lipase | 6 | 2011 | 133 | 0.480 |
Why?
|
| Nuclear Proteins | 6 | 2023 | 5799 | 0.470 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 103 | 0.460 |
Why?
|
| Obesity | 17 | 2024 | 12947 | 0.460 |
Why?
|
| Monocytes | 6 | 2014 | 2570 | 0.460 |
Why?
|
| Insulin Resistance | 11 | 2012 | 3964 | 0.460 |
Why?
|
| Myocardial Infarction | 15 | 2024 | 11461 | 0.440 |
Why?
|
| Adipogenesis | 5 | 2018 | 368 | 0.440 |
Why?
|
| Body Temperature Regulation | 3 | 2020 | 292 | 0.430 |
Why?
|
| Humans | 169 | 2024 | 761596 | 0.430 |
Why?
|
| Thermogenesis | 2 | 2020 | 475 | 0.420 |
Why?
|
| Endothelium | 2 | 2022 | 765 | 0.420 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2024 | 3763 | 0.410 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2020 | 364 | 0.410 |
Why?
|
| Hypobetalipoproteinemias | 1 | 2012 | 11 | 0.410 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 1027 | 0.390 |
Why?
|
| Phospholipids | 3 | 2024 | 786 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2024 | 2242 | 0.390 |
Why?
|
| Histones | 2 | 2020 | 2580 | 0.390 |
Why?
|
| Chemotaxis | 4 | 2024 | 598 | 0.390 |
Why?
|
| Animals | 62 | 2024 | 168475 | 0.380 |
Why?
|
| Systole | 1 | 2014 | 936 | 0.380 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 343 | 0.380 |
Why?
|
| Oxidation-Reduction | 5 | 2024 | 2231 | 0.380 |
Why?
|
| Cholesterol, HDL | 4 | 2020 | 1814 | 0.380 |
Why?
|
| Mice | 42 | 2024 | 81539 | 0.370 |
Why?
|
| Benzoxazoles | 2 | 2024 | 90 | 0.370 |
Why?
|
| Gluconeogenesis | 1 | 2012 | 185 | 0.370 |
Why?
|
| Glucose | 5 | 2018 | 4347 | 0.370 |
Why?
|
| Fenofibrate | 3 | 2007 | 87 | 0.370 |
Why?
|
| Sphingosine | 1 | 2013 | 308 | 0.370 |
Why?
|
| Lysophospholipids | 1 | 2013 | 338 | 0.360 |
Why?
|
| Overweight | 6 | 2024 | 2417 | 0.360 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2010 | 8 | 0.350 |
Why?
|
| Cells, Cultured | 18 | 2019 | 18966 | 0.350 |
Why?
|
| Diabetic Foot | 2 | 2024 | 380 | 0.340 |
Why?
|
| Gene Expression Regulation | 15 | 2020 | 11904 | 0.340 |
Why?
|
| Aortic Valve | 1 | 2019 | 1955 | 0.340 |
Why?
|
| Liver | 7 | 2013 | 7528 | 0.340 |
Why?
|
| Energy Metabolism | 3 | 2020 | 2882 | 0.340 |
Why?
|
| Mice, Knockout | 17 | 2024 | 14417 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2014 | 4352 | 0.330 |
Why?
|
| Incretins | 1 | 2010 | 99 | 0.330 |
Why?
|
| Hypercholesterolemia | 4 | 2023 | 1141 | 0.320 |
Why?
|
| Clinical Medicine | 1 | 2010 | 145 | 0.310 |
Why?
|
| Quinazolinones | 2 | 2020 | 221 | 0.310 |
Why?
|
| Signal Transduction | 14 | 2023 | 23447 | 0.310 |
Why?
|
| Retinaldehyde | 1 | 2007 | 24 | 0.290 |
Why?
|
| Tibia | 1 | 2013 | 1070 | 0.290 |
Why?
|
| Isoenzymes | 1 | 2012 | 1687 | 0.290 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2011 | 311 | 0.290 |
Why?
|
| Vascular Diseases | 3 | 2024 | 1161 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 18 | 2024 | 22174 | 0.280 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 2190 | 0.280 |
Why?
|
| Femur | 1 | 2013 | 1307 | 0.280 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 4615 | 0.280 |
Why?
|
| Lipolysis | 5 | 2007 | 212 | 0.280 |
Why?
|
| Prediabetic State | 3 | 2013 | 545 | 0.270 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2023 | 1119 | 0.270 |
Why?
|
| Hyperglycemia | 4 | 2014 | 1376 | 0.270 |
Why?
|
| Lipoproteins | 4 | 2023 | 881 | 0.270 |
Why?
|
| Hypertension | 5 | 2023 | 8540 | 0.260 |
Why?
|
| Lipoproteins, LDL | 4 | 2004 | 642 | 0.260 |
Why?
|
| Growth Inhibitors | 1 | 2007 | 378 | 0.260 |
Why?
|
| Azepines | 3 | 2020 | 329 | 0.260 |
Why?
|
| Registries | 7 | 2024 | 8225 | 0.250 |
Why?
|
| Coronary Vessels | 5 | 2024 | 3096 | 0.250 |
Why?
|
| Heart Failure | 8 | 2024 | 11671 | 0.250 |
Why?
|
| Leukocytes | 4 | 2007 | 2026 | 0.250 |
Why?
|
| beta Carotene | 1 | 2006 | 523 | 0.240 |
Why?
|
| Carotid Arteries | 5 | 2020 | 941 | 0.240 |
Why?
|
| Peripheral Arterial Disease | 3 | 2023 | 1273 | 0.240 |
Why?
|
| Peroxisome Proliferators | 2 | 2002 | 6 | 0.240 |
Why?
|
| Acetylation | 2 | 2020 | 1055 | 0.240 |
Why?
|
| Ligands | 8 | 2012 | 3272 | 0.240 |
Why?
|
| Physician's Role | 1 | 2011 | 917 | 0.230 |
Why?
|
| Gangrene | 1 | 2024 | 91 | 0.230 |
Why?
|
| Coronary Disease | 6 | 2006 | 5914 | 0.230 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 683 | 0.230 |
Why?
|
| Tretinoin | 2 | 2019 | 519 | 0.230 |
Why?
|
| Male | 61 | 2024 | 360846 | 0.220 |
Why?
|
| Alkaline Phosphatase | 2 | 2019 | 864 | 0.220 |
Why?
|
| Cell Adhesion | 5 | 2014 | 3088 | 0.220 |
Why?
|
| Macrophages | 6 | 2024 | 5767 | 0.220 |
Why?
|
| Adipocytes | 5 | 2020 | 1194 | 0.220 |
Why?
|
| Female | 57 | 2024 | 392705 | 0.210 |
Why?
|
| Porphyrias, Hepatic | 1 | 2022 | 6 | 0.210 |
Why?
|
| Butyrates | 2 | 2024 | 169 | 0.210 |
Why?
|
| RNA Polymerase II | 3 | 2016 | 539 | 0.210 |
Why?
|
| Eligibility Determination | 2 | 2017 | 421 | 0.210 |
Why?
|
| Latin America | 1 | 2024 | 410 | 0.210 |
Why?
|
| Antirheumatic Agents | 3 | 2024 | 1373 | 0.210 |
Why?
|
| Thiazoles | 5 | 2002 | 1517 | 0.200 |
Why?
|
| Middle Aged | 42 | 2024 | 220921 | 0.200 |
Why?
|
| Triazoles | 3 | 2020 | 903 | 0.200 |
Why?
|
| Prostaglandin D2 | 5 | 2008 | 108 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2022 | 118 | 0.200 |
Why?
|
| Weight Loss | 3 | 2024 | 2684 | 0.200 |
Why?
|
| Risk Factors | 27 | 2024 | 74213 | 0.190 |
Why?
|
| Dietary Fats | 2 | 2010 | 1995 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatases | 3 | 1992 | 457 | 0.190 |
Why?
|
| Endothelial Cells | 6 | 2023 | 3549 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2004 | 1809 | 0.190 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 2001 | 9 | 0.190 |
Why?
|
| Coronary Circulation | 2 | 2024 | 1569 | 0.190 |
Why?
|
| Biology | 1 | 2023 | 290 | 0.190 |
Why?
|
| Anticholesteremic Agents | 4 | 2020 | 966 | 0.190 |
Why?
|
| Collagenases | 2 | 1998 | 222 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 4576 | 0.190 |
Why?
|
| Simvastatin | 2 | 2001 | 346 | 0.180 |
Why?
|
| MicroRNAs | 3 | 2023 | 3816 | 0.180 |
Why?
|
| Retinol-Binding Proteins | 1 | 2020 | 67 | 0.180 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 973 | 0.180 |
Why?
|
| Receptors, sigma | 1 | 2020 | 45 | 0.180 |
Why?
|
| Mice, Obese | 3 | 2011 | 420 | 0.180 |
Why?
|
| Microcirculation | 2 | 2024 | 1272 | 0.180 |
Why?
|
| North America | 1 | 2024 | 1276 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2014 | 4399 | 0.170 |
Why?
|
| Cardiology | 1 | 2011 | 1656 | 0.170 |
Why?
|
| Bone Density | 1 | 2013 | 3551 | 0.170 |
Why?
|
| Treatment Outcome | 20 | 2024 | 64685 | 0.170 |
Why?
|
| Risk Assessment | 16 | 2024 | 23996 | 0.170 |
Why?
|
| HIV Infections | 5 | 2024 | 17354 | 0.170 |
Why?
|
| Hypertriglyceridemia | 3 | 2011 | 293 | 0.170 |
Why?
|
| Apolipoprotein C-III | 2 | 2019 | 211 | 0.170 |
Why?
|
| Troponin T | 2 | 2024 | 780 | 0.170 |
Why?
|
| Blood Pressure | 2 | 2023 | 8481 | 0.170 |
Why?
|
| Hydrolysis | 3 | 2011 | 664 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 4369 | 0.160 |
Why?
|
| Oxidative Stress | 4 | 2010 | 3113 | 0.160 |
Why?
|
| Thromboplastin | 1 | 2001 | 286 | 0.160 |
Why?
|
| Drug Tolerance | 1 | 2020 | 367 | 0.160 |
Why?
|
| Pravastatin | 1 | 2001 | 392 | 0.160 |
Why?
|
| Aged | 31 | 2024 | 169310 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 3 | 2023 | 1349 | 0.160 |
Why?
|
| Double-Blind Method | 8 | 2024 | 12341 | 0.160 |
Why?
|
| Neointima | 1 | 2019 | 133 | 0.150 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 1363 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 2645 | 0.150 |
Why?
|
| Isotretinoin | 1 | 2019 | 134 | 0.150 |
Why?
|
| Cell Transdifferentiation | 1 | 2019 | 186 | 0.150 |
Why?
|
| Aortic Diseases | 1 | 2024 | 735 | 0.150 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1999 | 277 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 857 | 0.150 |
Why?
|
| Disease Progression | 4 | 2024 | 13510 | 0.140 |
Why?
|
| Vascular Grafting | 1 | 2019 | 162 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 10212 | 0.140 |
Why?
|
| Angina, Unstable | 1 | 2001 | 888 | 0.140 |
Why?
|
| NF-kappa B | 7 | 2016 | 2490 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 840 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 10766 | 0.140 |
Why?
|
| Cardiovascular System | 2 | 2021 | 834 | 0.140 |
Why?
|
| Chromans | 4 | 2002 | 117 | 0.140 |
Why?
|
| Arrestins | 1 | 2017 | 73 | 0.140 |
Why?
|
| Adiposity | 3 | 2014 | 1879 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 1998 | 0.140 |
Why?
|
| 3T3-L1 Cells | 2 | 2007 | 209 | 0.140 |
Why?
|
| Metalloproteases | 1 | 2016 | 61 | 0.130 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 3449 | 0.130 |
Why?
|
| Interferon-gamma | 2 | 2002 | 3162 | 0.130 |
Why?
|
| Transfection | 6 | 2020 | 5774 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2017 | 242 | 0.130 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2019 | 395 | 0.130 |
Why?
|
| RNA, Messenger | 14 | 2016 | 12794 | 0.130 |
Why?
|
| Mesoderm | 1 | 2019 | 674 | 0.130 |
Why?
|
| Adiponectin | 3 | 2018 | 1113 | 0.130 |
Why?
|
| Stroke Volume | 3 | 2024 | 5496 | 0.130 |
Why?
|
| E-Selectin | 2 | 2015 | 576 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 2273 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 2178 | 0.130 |
Why?
|
| Fasting | 2 | 2020 | 1603 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2024 | 12953 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 829 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 2472 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2012 | 1699 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 1069 | 0.120 |
Why?
|
| Pyrimidines | 4 | 2002 | 3028 | 0.120 |
Why?
|
| Gene Expression | 6 | 2011 | 7581 | 0.120 |
Why?
|
| SOXF Transcription Factors | 1 | 2014 | 31 | 0.120 |
Why?
|
| DNA-Binding Proteins | 4 | 2006 | 9610 | 0.120 |
Why?
|
| Orphan Nuclear Receptors | 2 | 2006 | 63 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2000 | 1113 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2010 | 3429 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 7391 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 218 | 0.120 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 1532 | 0.110 |
Why?
|
| Cell Movement | 3 | 2014 | 5205 | 0.110 |
Why?
|
| Stroke | 5 | 2023 | 9758 | 0.110 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 256 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2023 | 3430 | 0.110 |
Why?
|
| Response Elements | 1 | 2015 | 309 | 0.110 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 625 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2013 | 8321 | 0.110 |
Why?
|
| Fatty Liver | 2 | 2011 | 790 | 0.110 |
Why?
|
| Glucosides | 1 | 2018 | 512 | 0.110 |
Why?
|
| Alkanesulfonates | 1 | 2012 | 15 | 0.110 |
Why?
|
| Tunica Intima | 1 | 2015 | 459 | 0.110 |
Why?
|
| Smad Proteins | 1 | 2013 | 156 | 0.110 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2013 | 158 | 0.100 |
Why?
|
| Phenylpropionates | 1 | 2012 | 35 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 5 | 2015 | 5790 | 0.100 |
Why?
|
| Incidence | 9 | 2024 | 21355 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3492 | 0.100 |
Why?
|
| Blotting, Northern | 3 | 2003 | 1545 | 0.100 |
Why?
|
| Apolipoprotein A-I | 2 | 2021 | 299 | 0.100 |
Why?
|
| American Heart Association | 3 | 2023 | 1039 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 1723 | 0.100 |
Why?
|
| Carrier Proteins | 2 | 2019 | 4937 | 0.100 |
Why?
|
| Sodium | 1 | 2018 | 1588 | 0.100 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2013 | 122 | 0.100 |
Why?
|
| Hepatocytes | 2 | 2012 | 1233 | 0.100 |
Why?
|
| Calorimetry | 1 | 2012 | 129 | 0.100 |
Why?
|
| Insulin | 3 | 2014 | 6597 | 0.100 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 219 | 0.100 |
Why?
|
| Cattle | 5 | 2010 | 3849 | 0.100 |
Why?
|
| Intermittent Claudication | 1 | 2014 | 304 | 0.100 |
Why?
|
| Oxygen | 1 | 2023 | 4227 | 0.100 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 456 | 0.100 |
Why?
|
| Lipogenesis | 1 | 2013 | 214 | 0.100 |
Why?
|
| Stem Cell Factor | 1 | 2012 | 195 | 0.100 |
Why?
|
| Adipose Tissue, Brown | 2 | 2020 | 764 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 2113 | 0.100 |
Why?
|
| Oxazoles | 1 | 2012 | 199 | 0.090 |
Why?
|
| Inflammation Mediators | 2 | 2024 | 1886 | 0.090 |
Why?
|
| Blotting, Western | 3 | 2012 | 5035 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5485 | 0.090 |
Why?
|
| Adult | 23 | 2024 | 221210 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 916 | 0.090 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 750 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1992 | 430 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2014 | 790 | 0.090 |
Why?
|
| Apolipoproteins B | 2 | 2023 | 386 | 0.090 |
Why?
|
| Oxazines | 1 | 2012 | 350 | 0.090 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 296 | 0.090 |
Why?
|
| Anilides | 1 | 2013 | 411 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 705 | 0.090 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 877 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2012 | 9542 | 0.080 |
Why?
|
| Rural Population | 1 | 2020 | 2287 | 0.080 |
Why?
|
| COS Cells | 1 | 2011 | 1130 | 0.080 |
Why?
|
| Saphenous Vein | 4 | 2000 | 516 | 0.080 |
Why?
|
| Osteopontin | 1 | 2011 | 301 | 0.080 |
Why?
|
| Glycine | 1 | 2012 | 663 | 0.080 |
Why?
|
| Diet | 1 | 2007 | 8075 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 2139 | 0.080 |
Why?
|
| Catalytic Domain | 1 | 2011 | 705 | 0.080 |
Why?
|
| Osteoblasts | 1 | 2014 | 1143 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2010 | 632 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 2 | 2004 | 908 | 0.080 |
Why?
|
| Protein Binding | 2 | 2014 | 9353 | 0.080 |
Why?
|
| Thioredoxins | 1 | 2010 | 202 | 0.080 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 502 | 0.080 |
Why?
|
| Amino Acids | 1 | 2015 | 1718 | 0.080 |
Why?
|
| Retrospective Studies | 15 | 2024 | 80647 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2020 | 3677 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5112 | 0.080 |
Why?
|
| Skin | 1 | 2022 | 4484 | 0.080 |
Why?
|
| Flavonoids | 1 | 2011 | 445 | 0.080 |
Why?
|
| Myocardial Revascularization | 2 | 2023 | 790 | 0.080 |
Why?
|
| Endothelins | 1 | 2008 | 127 | 0.080 |
Why?
|
| Apolipoproteins A | 2 | 2023 | 95 | 0.080 |
Why?
|
| Leukotriene E4 | 1 | 2008 | 75 | 0.080 |
Why?
|
| Thiophenes | 1 | 2012 | 569 | 0.080 |
Why?
|
| Myocardium | 1 | 2021 | 4725 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 1738 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2021 | 2781 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 3530 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 494 | 0.070 |
Why?
|
| Receptors, LDL | 2 | 2024 | 488 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4281 | 0.070 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 8002 | 0.070 |
Why?
|
| Ion Channels | 1 | 2012 | 1040 | 0.070 |
Why?
|
| Walking | 1 | 2014 | 1198 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2016 | 1228 | 0.070 |
Why?
|
| Genes | 2 | 1992 | 1823 | 0.070 |
Why?
|
| Angiotensin II | 2 | 2022 | 849 | 0.070 |
Why?
|
| Cytokines | 3 | 2007 | 7396 | 0.070 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2006 | 8 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 15266 | 0.070 |
Why?
|
| C-Reactive Protein | 3 | 2024 | 3826 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2024 | 4125 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 976 | 0.070 |
Why?
|
| Aryldialkylphosphatase | 1 | 2006 | 64 | 0.070 |
Why?
|
| Pericytes | 1 | 2009 | 293 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2006 | 127 | 0.070 |
Why?
|
| United States | 11 | 2023 | 72340 | 0.070 |
Why?
|
| RNA Interference | 2 | 2012 | 2832 | 0.070 |
Why?
|
| Chromatin | 2 | 2014 | 2961 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 1866 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 1935 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 670 | 0.060 |
Why?
|
| Rats | 5 | 2019 | 23741 | 0.060 |
Why?
|
| Heart Transplantation | 2 | 2013 | 3233 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1616 | 0.060 |
Why?
|
| Podocytes | 1 | 2009 | 405 | 0.060 |
Why?
|
| Microvessels | 1 | 2009 | 577 | 0.060 |
Why?
|
| Homeostasis | 2 | 2013 | 3323 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2011 | 1590 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 611 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2457 | 0.060 |
Why?
|
| Uganda | 2 | 2020 | 1332 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 3792 | 0.060 |
Why?
|
| Ischemia | 2 | 2023 | 1884 | 0.060 |
Why?
|
| Learning | 1 | 2014 | 1740 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2024 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1664 | 0.060 |
Why?
|
| Linoleic Acids | 1 | 2003 | 39 | 0.060 |
Why?
|
| Sex Factors | 3 | 2024 | 10554 | 0.060 |
Why?
|
| Blood Glucose | 4 | 2014 | 6391 | 0.060 |
Why?
|
| Apoprotein(a) | 1 | 2023 | 17 | 0.060 |
Why?
|
| Vitamin A | 2 | 2020 | 613 | 0.060 |
Why?
|
| Primary Prevention | 2 | 2012 | 1186 | 0.060 |
Why?
|
| Foam Cells | 1 | 2003 | 68 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 540 | 0.050 |
Why?
|
| Electrochemistry | 1 | 2003 | 145 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 517 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 191 | 0.050 |
Why?
|
| Viral Load | 1 | 2012 | 3332 | 0.050 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2022 | 27 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 681 | 0.050 |
Why?
|
| Prevalence | 3 | 2024 | 15733 | 0.050 |
Why?
|
| Patient Selection | 1 | 2015 | 4244 | 0.050 |
Why?
|
| Inhibins | 1 | 2023 | 210 | 0.050 |
Why?
|
| Cholesterol, Dietary | 2 | 2015 | 224 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2012 | 2856 | 0.050 |
Why?
|
| Prognosis | 4 | 2024 | 29629 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2010 | 2665 | 0.050 |
Why?
|
| Radiography | 1 | 2013 | 6965 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2022 | 108 | 0.050 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cell Line | 2 | 2011 | 15601 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 1112 | 0.050 |
Why?
|
| Sulfur | 1 | 2022 | 162 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 1274 | 0.050 |
Why?
|
| Interleukin-9 | 1 | 2022 | 62 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 2576 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3769 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 15843 | 0.050 |
Why?
|
| Pharmacists | 1 | 2024 | 260 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2021 | 3208 | 0.050 |
Why?
|
| Gemfibrozil | 1 | 2001 | 30 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 9177 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 58984 | 0.050 |
Why?
|
| Glycoproteins | 2 | 1986 | 2203 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2022 | 234 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2001 | 71 | 0.050 |
Why?
|
| Withholding Treatment | 2 | 2017 | 617 | 0.050 |
Why?
|
| Mast Cells | 1 | 2008 | 1392 | 0.050 |
Why?
|
| Rabbits | 1 | 2007 | 4772 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 1749 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2010 | 2645 | 0.050 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2020 | 57 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2008 | 3597 | 0.040 |
Why?
|
| Heme | 1 | 2022 | 313 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2020 | 135 | 0.040 |
Why?
|
| Hyperlipidemias | 2 | 2002 | 771 | 0.040 |
Why?
|
| Glucose Clamp Technique | 2 | 2011 | 263 | 0.040 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2024 | 323 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2003 | 589 | 0.040 |
Why?
|
| California | 1 | 2024 | 1430 | 0.040 |
Why?
|
| Methionine | 1 | 2022 | 572 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2004 | 1968 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 371 | 0.040 |
Why?
|
| Spironolactone | 1 | 2023 | 412 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2013 | 10451 | 0.040 |
Why?
|
| Anisotropy | 1 | 2023 | 1283 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2011 | 7859 | 0.040 |
Why?
|
| RNA | 2 | 2022 | 2725 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2019 | 69 | 0.040 |
Why?
|
| Time Factors | 4 | 2024 | 39969 | 0.040 |
Why?
|
| Androstenes | 1 | 2020 | 181 | 0.040 |
Why?
|
| Homocysteine | 1 | 2022 | 638 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 504 | 0.040 |
Why?
|
| Models, Biological | 3 | 2008 | 9469 | 0.040 |
Why?
|
| Patient Education as Topic | 2 | 2024 | 2319 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 344 | 0.040 |
Why?
|
| U937 Cells | 1 | 1999 | 261 | 0.040 |
Why?
|
| Vasomotor System | 1 | 1999 | 207 | 0.040 |
Why?
|
| Necrosis | 1 | 2023 | 1611 | 0.040 |
Why?
|
| Fish Oils | 1 | 2002 | 483 | 0.040 |
Why?
|
| Young Adult | 6 | 2023 | 59260 | 0.040 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2024 | 575 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 422 | 0.040 |
Why?
|
| Dinoprost | 1 | 1998 | 138 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 1999 | 362 | 0.040 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 5337 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2024 | 4471 | 0.040 |
Why?
|
| Kidney | 2 | 2024 | 7048 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 1739 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2019 | 41495 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2024 | 999 | 0.040 |
Why?
|
| Mortality | 2 | 2021 | 2902 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 588 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2007 | 3905 | 0.040 |
Why?
|
| Muscles | 2 | 2013 | 1576 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1998 | 255 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2013 | 4811 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 1241 | 0.040 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2020 | 303 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2006 | 2910 | 0.040 |
Why?
|
| Software | 1 | 2011 | 4434 | 0.040 |
Why?
|
| DNA | 4 | 2001 | 7213 | 0.040 |
Why?
|
| Luciferases | 1 | 1999 | 714 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 817 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 539 | 0.040 |
Why?
|
| Base Sequence | 5 | 1992 | 12441 | 0.040 |
Why?
|
| Kidney Diseases | 2 | 2024 | 2091 | 0.030 |
Why?
|
| Gelatin | 1 | 1998 | 220 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 16990 | 0.030 |
Why?
|
| Transplants | 1 | 2019 | 206 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12059 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 1039 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 2206 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1516 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 1410 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 1990 | 3889 | 0.030 |
Why?
|
| Mass Screening | 1 | 2012 | 5429 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 618 | 0.030 |
Why?
|
| Blood Coagulation | 2 | 1999 | 1154 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2021 | 836 | 0.030 |
Why?
|
| Cloning, Molecular | 3 | 1992 | 4174 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2019 | 474 | 0.030 |
Why?
|
| Folic Acid | 1 | 2022 | 1323 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 1964 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 8710 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8466 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 26129 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 1704 | 0.030 |
Why?
|
| Syndrome | 1 | 2001 | 3267 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 1844 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2002 | 1889 | 0.030 |
Why?
|
| Telemedicine | 2 | 2024 | 3052 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1999 | 1529 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2023 | 4021 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2049 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 2015 | 96 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1612 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 11076 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 803 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1186 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3306 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 1509 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2822 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2024 | 2220 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 931 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 1421 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2022 | 2526 | 0.030 |
Why?
|
| Algorithms | 3 | 2020 | 14033 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2016 | 9647 | 0.030 |
Why?
|
| Natural Language Processing | 2 | 2013 | 1163 | 0.030 |
Why?
|
| Aftercare | 1 | 2019 | 914 | 0.030 |
Why?
|
| Risk | 3 | 2012 | 9610 | 0.030 |
Why?
|
| Disease Management | 1 | 2024 | 2508 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5672 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1992 | 13446 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2019 | 1475 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2000 | 1651 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 3688 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2002 | 1390 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 590 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 1302 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3701 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 4243 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 662 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 1992 | 422 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2023 | 5247 | 0.030 |
Why?
|
| Physicians | 1 | 1990 | 4591 | 0.030 |
Why?
|
| Vaccinium macrocarpon | 1 | 2011 | 11 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2013 | 405 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 6534 | 0.020 |
Why?
|
| Apolipoprotein C-II | 1 | 2011 | 15 | 0.020 |
Why?
|
| Receptors, Adiponectin | 1 | 2011 | 81 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 616 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1992 | 777 | 0.020 |
Why?
|
| Graft Survival | 1 | 2002 | 3820 | 0.020 |
Why?
|
| Age Factors | 2 | 2019 | 18399 | 0.020 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 6484 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 4514 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1992 | 17635 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 1992 | 2180 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1992 | 301 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 322 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2011 | 209 | 0.020 |
Why?
|
| Cause of Death | 1 | 2021 | 3683 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 2013 | 590 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2136 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 945 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2020 | 22176 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2024 | 54423 | 0.020 |
Why?
|
| Systems Integration | 1 | 2011 | 426 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2019 | 1937 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 3124 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2014 | 836 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 30053 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 2011 | 326 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2021 | 2499 | 0.020 |
Why?
|
| Protein C | 2 | 1986 | 133 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 878 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 3415 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 1726 | 0.020 |
Why?
|
| Calcium | 1 | 2021 | 5722 | 0.020 |
Why?
|
| Health | 1 | 2011 | 398 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1999 | 4142 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Leukotriene D4 | 1 | 2008 | 33 | 0.020 |
Why?
|
| Tyrosine | 1 | 1992 | 1440 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2011 | 598 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 1646 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2811 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 794 | 0.020 |
Why?
|
| Body Composition | 1 | 2017 | 2426 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2002 | 561 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7828 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 400 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2010 | 672 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5971 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 36426 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 12463 | 0.020 |
Why?
|
| Thiocarbamates | 1 | 2006 | 30 | 0.020 |
Why?
|
| Comorbidity | 1 | 2021 | 10508 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3600 | 0.020 |
Why?
|
| Documentation | 1 | 2013 | 897 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 2127 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 2254 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 1990 | 544 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2011 | 613 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 4016 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 18255 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 211 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 2091 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 615 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1985 | 166 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4420 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 1443 | 0.010 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3713 | 0.010 |
Why?
|
| Hospitalization | 1 | 2024 | 10721 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 1668 | 0.010 |
Why?
|
| Proline | 1 | 2006 | 457 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2011 | 2919 | 0.010 |
Why?
|
| Chemokines | 1 | 2008 | 959 | 0.010 |
Why?
|
| Fluoroimmunoassay | 1 | 2002 | 30 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 4807 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 10194 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 6075 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1986 | 774 | 0.010 |
Why?
|
| Cell Survival | 1 | 2012 | 5791 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 930 | 0.010 |
Why?
|
| Collagen | 1 | 2010 | 2638 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 426 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5440 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2018 | 4687 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 981 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1985 | 1132 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 601 | 0.010 |
Why?
|
| Body Weight | 1 | 2011 | 4618 | 0.010 |
Why?
|
| Chemokine CXCL11 | 1 | 2000 | 43 | 0.010 |
Why?
|
| Microbodies | 1 | 2000 | 36 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1986 | 1023 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11530 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2013 | 4446 | 0.010 |
Why?
|
| Chemokine CXCL9 | 1 | 2000 | 135 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 808 | 0.010 |
Why?
|
| Heart | 1 | 2013 | 4404 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13255 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1986 | 1071 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 364 | 0.010 |
Why?
|
| Leukemia | 1 | 2008 | 1522 | 0.010 |
Why?
|
| Smoking | 1 | 2016 | 9053 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12723 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2000 | 238 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2000 | 316 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 3029 | 0.010 |
Why?
|
| Mevalonic Acid | 1 | 1998 | 46 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 6056 | 0.010 |
Why?
|
| Lovastatin | 1 | 1998 | 115 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39106 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 652 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8527 | 0.010 |
Why?
|
| Health Promotion | 1 | 2008 | 2214 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14665 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 9490 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 4358 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2000 | 907 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 1171 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 3442 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1992 | 365 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1992 | 456 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 6864 | 0.010 |
Why?
|
| Metformin | 1 | 1999 | 906 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8633 | 0.010 |
Why?
|
| Antioxidants | 1 | 1999 | 1668 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 779 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2003 | 3066 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 3767 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1992 | 2748 | 0.000 |
Why?
|
| Genotype | 1 | 2003 | 12990 | 0.000 |
Why?
|
| Deoxyribonuclease BamHI | 1 | 1985 | 17 | 0.000 |
Why?
|
| Factor X | 1 | 1985 | 64 | 0.000 |
Why?
|
| Factor IX | 1 | 1985 | 77 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 550 | 0.000 |
Why?
|
| Prothrombin | 1 | 1985 | 191 | 0.000 |
Why?
|
| Child | 1 | 2012 | 80158 | 0.000 |
Why?
|
| Adolescent | 1 | 2011 | 88326 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 17904 | 0.000 |
Why?
|
| Brain | 1 | 1992 | 27121 | 0.000 |
Why?
|